Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Related Articles by Review for PubMed (Select 22904646)

1.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.

Fisher R, Larkin J.

Cancer Manag Res. 2012;4:243-52. doi: 10.2147/CMAR.S25284. Epub 2012 Aug 8.

2.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
3.

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

Sharma A, Shah SR, Illum H, Dowell J.

Drugs. 2012 Dec 3;72(17):2207-22. doi: 10.2165/11640870-000000000-00000. Review.

PMID:
23116250
4.

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.

Heakal Y, Kester M, Savage S.

Ann Pharmacother. 2011 Nov;45(11):1399-405. doi: 10.1345/aph.1Q363. Epub 2011 Oct 25. Review.

PMID:
22028422
5.

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V, Queirolo P.

Onco Targets Ther. 2015 Jan 16;8:157-68. doi: 10.2147/OTT.S39096. eCollection 2015. Review.

6.

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.

Rutkowski P, Blank C.

Expert Opin Drug Saf. 2014 Sep;13(9):1249-58. doi: 10.1517/14740338.2014.939954. Epub 2014 Jul 11. Review.

PMID:
25014231
7.

Integrating new therapies in the treatment of advanced melanoma.

Curti BD, Urba WJ.

Curr Treat Options Oncol. 2012 Sep;13(3):327-39. doi: 10.1007/s11864-012-0201-9. Review.

PMID:
22743761
8.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753
9.

Vemurafenib: the road to personalized medicine in melanoma.

Amaria RN, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Feb;48(2):109-18. doi: 10.1358/dot.2012.48.2.1745274. Review.

PMID:
22384451
10.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
11.

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.

Dean E, Lorigan P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1437-48. doi: 10.1586/era.12.124. Review.

PMID:
23249108
12.

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.

Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR.

Ther Adv Med Oncol. 2014 Nov;6(6):262-6. doi: 10.1177/1758834014548187. Review.

13.

Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research.

Bhatia P, Friedlander P, Zakaria EA, Kandil E.

Ann Transl Med. 2015 Feb;3(2):24. doi: 10.3978/j.issn.2305-5839.2014.12.05. Review. Erratum in: Ann Transl Med. 2015 Mar;3(4):60.

14.

Combination therapies for the treatment of advanced melanoma: a review of current evidence.

Voskoboynik M, Arkenau HT.

Biochem Res Int. 2014;2014:307059. doi: 10.1155/2014/307059. Epub 2014 Feb 12. Review.

15.

[What's new in dermato-oncology?].

Basset-SĂ©guin N.

Ann Dermatol Venereol. 2011 Dec;138 Suppl 4:S253-62. doi: 10.1016/S0151-9638(11)70099-0. Review. French.

PMID:
22202647
16.

Co-development of a companion diagnostic for targeted cancer therapy.

Cheng S, Koch WH, Wu L.

N Biotechnol. 2012 Sep 15;29(6):682-8. doi: 10.1016/j.nbt.2012.02.002. Epub 2012 Feb 25. Review.

PMID:
22391147
17.

New drugs in melanoma: it's a whole new world.

Eggermont AM, Robert C.

Eur J Cancer. 2011 Sep;47(14):2150-7. doi: 10.1016/j.ejca.2011.06.052. Epub 2011 Jul 27. Review.

PMID:
21802280
18.

Vemurafenib: the first drug approved for BRAF-mutant cancer.

Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P.

Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12. Review.

PMID:
23060265
19.

[BRAF mutation: a novel approach in targeted melanoma therapy].

Arenbergerová M, Puzanov I.

Klin Onkol. 2012;25(5):323-8. Review. Czech.

PMID:
23102192
20.

BRAF inhibitors: the current and the future.

Zhang W.

Curr Opin Pharmacol. 2015 Aug;23:68-73. doi: 10.1016/j.coph.2015.05.015. Epub 2015 Jun 10. Review.

PMID:
26072431
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk